RATIONALE: Gathering information about patients with chronic myelogenous leukemia may help doctors learn more about the disease and find better methods of treatment and on-going care. PURPOSE: This natural history study is collecting health information and disease-related information over time from patients with newly diagnosed chronic myelogenous leukemia.
OBJECTIVES: * Determine the impact of current procedures for diagnosis, management, and follow-up on disease status of patients with newly diagnosed chronic myelogenous leukemia (CML). * Determine the natural history of patients with CML who achieve response to imatinib mesylate. * Determine the health perceptions, symptoms, insurance issues, and work issues of these patients. * Determine whether medication compliance and planned dose reduction affect imatinib mesylate effectiveness in these patients. * Determine the molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate in these patients. OUTLINE: This is a longitudinal, prospective, cohort study. Patients complete quality of life, functional status, medical and treatment history, and medication questionnaires at baseline and then every 6 months for 5 years. Blood samples are collected at baseline and then every 6 months for 5 years. Specimens may be examined in the future in gene array studies and mutation analyses.
Study Type
OBSERVATIONAL
Enrollment
48
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
Impact of current procedures for diagnosis, management, and follow-up on disease status
Time frame: 5 years
Natural history of patients with chronic myelogenous leukemia who achieve response to imatinib mesylate
Time frame: 5 years
Health perceptions, symptoms, insurance issues, and work issues
Time frame: 5 years
Affect of medication compliance and planned dose reduction on imatinib mesylate effectiveness
Time frame: 5 years
Molecular and biologic factors associated with disease progression and good and poor response to imatinib mesylate
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.